Viva Biotech Announces Its 2026 Interim Results: AI Sparks New Paradigm in Drug R&D, CDMO Commercial Manufacturing Accelerates Revenue Growth

Viva Biotech Holdings reported 1H26 revenue of RMB1,006.5m (+21.0% YoY) and gross profit of RMB341.7m with a 34.0% gross margin (+0.7% YoY), helped by Langhua Pharmaceutical’s CDMO growth. However, 1H26 net profit fell to RMB100.9m (adjusted non-IFRS RMB128.3m) due to lower investment income, adverse FX, and higher R&D expenses. CRO revenue reached RMB405.1m and the company expects full-year 2026 growth at or above the current level, while new CDMO commercialization projects drove Langhua revenue to RMB601.4m (+47.0% YoY) and gross profit to RMB175.1m (+12.9% YoY).

Analysis

This is less a clean “beat” than a mix-shift story: the market should focus on whether the CDMO commercialization pipeline can keep absorbing fixed plant and technical overhead, because that is what turns top-line growth into durable EBITDA expansion. The key positive is that peptide and complex-modality exposure gives the company a better shot at pricing power than commoditized discovery services, but that advantage only matters if utilization rises faster than capex and R&D spend.

The main second-order effect is competitive. If the AI-enabled wet-lab narrative is real, it supports higher share of wallet with global pharma, but larger China CRO/CDMO peers and global players can copy “AI” messaging quickly; the durable moat is more likely in structure-data depth, chemistry execution, and regulatory-grade manufacturing reliability. For the wider ecosystem, this is mildly supportive for peptide-enabled tools, oligo, and specialized process-chemistry suppliers, but it also raises the bar for smaller discovery boutiques that lack integrated manufacturing pathways.

Near term, the stock is more likely to trade on earnings quality than headline growth: non-operating gains, FX, and investment income are volatile, so any rerating needs proof that operating profit and cash flow are inflecting together. Over 1-3 months, watch H2 utilization and whether new commercial projects translate into better gross margin mix; over 6-18 months, the test is whether capacity expansion earns its cost of capital or just preserves growth at lower returns. The contrarian risk is that investors overpay for “AI + peptides” while the real driver remains cyclical CDMO demand and customer concentration.

Falsifier: if gross margin fails to hold in the mid-30s as revenue scales, or if commercial project conversion slows, the growth narrative should de-rate quickly.

Key Decisions for Investors

• No immediate aggressive long: treat VBIZF as a confirmation trade, not a momentum buy. Wait 1-2 quarters for evidence that operating margin and operating cash flow are rising together before initiating size.
• If liquidity allows, consider a small relative-value long VBIZF vs short a broader China biotech/CXO basket over 1-3 months, but only on follow-through in H2 utilization; thesis is that niche peptide/CDMO capability deserves a premium if commercialization scales.
• Set an alert around any gross margin slip below ~33% or a flattening of revenue growth next update; that would imply the mix benefit is peaking and should trigger de-risking.
• For the sector, favor suppliers/tools exposed to peptide, oligo, and structural biology workflows over generic discovery names; this is the cleaner second-order beneficiary if the AI-wet-lab cycle is real.
• Avoid adding on the basis of non-operating profit expansion; if the next report shows operating profit lagging again, the stock should be treated as a low-conviction turnaround rather than a sustainable growth compounder.